摘要
目的探讨噻托溴铵联合沙美特罗替卡松粉吸入治疗慢性阻塞性肺疾病(COPD)稳定期患者的临床疗效及其安全性。方法选取重庆市第九人民医院呼吸内科2014—2016年收治的COPD稳定期患者92例,随机分为对照组和观察组,各46例。对照组患者采用沙美特罗替卡松粉吸入治疗,观察组患者在对照组基础上给予噻托溴铵治疗,两组患者均持续治疗3个月。比较两组患者的临床疗效及治疗前后第1秒用力呼气容积(FEV_1)及用力肺活量(FVC),观察患者药物不良反应发生情况。结果观察组患者临床疗效优于对照组(P<0.05)。治疗前,两组患者FEV_1、FVC比较,差异无统计学意义(P>0.05);治疗后,观察组患者FEV_1、FVC高于对照组(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论采用噻托溴铵联合沙美特罗替卡松粉吸入治疗COPD稳定期患者的临床疗效确切,可有效改善患者肺功能,且安全性高。
Objective To investigate the clinical effect of tiotropium bromide combined with salmeterol xinafoate and fluticasone propionate in treating patients with chronic obstructive pulmonary disease(COPD) in stable stage.Methods A total of 92 cases of patients with COPD in stable stage were selected from 2014 to 2016 years in Department of Respiratory Disease in the Ninth People's Public Hospital in Chongqing City,which were randomly divided into control group and observation group,46 cases in each group.The control group was given salmeterol xinafoate and fluticasone propionate powder,observation group was given tiotropium bromide on the basis of control group,both groups were treated for 3 months.The clinical effect and FEV1,FVC levels before and after treatment were compared between the two groups,and the incidence of drug adverse reactions were observed.Results The clinical effect of observation group was better than control group(P〈0.05).Before treatment,no statistically significant differences of FEV1 or FVC was found between the two groups(P〈0.05);after treatment,the FEV1,FVC in observation group were higher than control group(P〉0.05).There was no statistically significant difference of incidence of drug adverse reactions between the two groups(P〉0.05).Conclusion Tiotropium bromide combined with salmeterol xinafoate and fluticasone propionate have an obviously clinical effect in treating COPD patients in stable stage,it can effectively improve the pulmonary function of patients,and with high safety.
作者
罗彬
周静
秦蓁
LUO Bin;ZHOU Jing;QIN Zhen(Faculty of Clinical Medicine, Chongqing Medical and Pharmaceutical College, Chongqing 401331, China)
出处
《临床合理用药杂志》
2018年第15期1-2,共2页
Chinese Journal of Clinical Rational Drug Use
关键词
肺疾病
慢性阻塞性
噻托溴铵
沙美特罗替卡松
治疗结果
安全性
Pulmonary disease
chronic obstructive
Tiotropium bromide
Salmeterol xinafoate and fluticasone propionate
Treatment outcome
Safety